



**Oxford BioDynamics Plc**

("OBD" or the "Company" and, together with its subsidiaries, the "Group")

**Board Changes**

**Oxford, UK - 17 March 2025** -Oxford BioDynamics Plc (AIM: OBD, the Company), a precision clinical diagnostics company bringing specific and sensitive tests to the practice of medicine based on its EpiSwitch® 3D genomics platform, is pleased to announce the appointment of Peter Presland to the Board as Non-Executive Director and Chair of the Company's Audit Committee.

Peter Presland is an experienced Non-Executive Director and Chairman with 50 years' experience in business, much of that at the highest levels of management within both public and private companies. A law graduate at King's College, University of London, he qualified as a Chartered Accountant with Arthur Andersen. In 1980, he joined C E Heath plc ("Heath"), a major publicly quoted international insurance group, as Group Accountant/Treasurer and became in 1985 the Group Finance Director. He was promoted to Heath's Group Chief Executive in 1990, and in 1996 led the demerger of Heath's computer services operations into a separate publicly listed company, Rebus Group plc, becoming its Chief Executive and in 1999 its Chairman.

Since 2001, Peter has pursued a portfolio non-executive career, becoming Chairman of a number of IT and financial services companies, including LINK, the UK ATM network, in 2003 where he led a major corporate governance change as well as the merger of LINK with Voca, the provider of the BACS service, becoming Chairman of VocaLink in 2007. Among other appointments, from 2012 to 2015, he served as Chairman of the Audit & Governance Committee of East Kent Hospitals NHS Trust, in 2017 was appointed to the board of Redx Pharma PLC, and in 2019 was asked to become Chairman of the Governance & Finance Committee of the Lord's Taverners, a high-profile charity.

As indicated in the announcement of the Company's preliminary results on 28 February 2025, Non-Executive Director and former Chairman Matthew Wakefield has stepped down from the Board, with effect from today.

Iain Ross, Executive Chairman of Oxford BioDynamics, said: "I am very pleased to welcome Peter to the OBD Board. I have seen at first hand the support and challenge he offers in a non-executive capacity. His professional background and extensive experience will complement the Board perfectly and, from a governance perspective, improve the balance of independence among our directors as a group."

"I would like again to extend my thanks to Matthew Wakefield for his service to OBD as Non-Executive Chairman from December 2020 until my recent appointment. Through his leadership of the Board over the last four years, Matthew has been unstinting in his support of the Company and its Management as well as in working to raise funds for the Company on several occasions. On behalf of the Board, I wish him every success in his future endeavours."

**-Ends-**

**For further details please contact:**

<b>Oxford BioDynamics Plc</b>	Tel: +44 (0)1865 518910
Iain Ross Executive Chairman Paul Stockdale, CFO	
<b>Shore Capital - Nominated Adviser and Broker</b>	Tel: +44 (0)20 7408 4090
Advisory: Stephane Auton / Lucy Bowden Broking: Fiona Conroy	
<b>OAK Securities - Joint Broker</b>	Tel: +44 (0)20 3973 3678
Jerry Keen / Henry Clarke / Damion Carruel	
<b>WG Partners - Joint Broker</b>	Tel: +44 (0)20 3705 9330
David Wilson / Claes Spång / Satheesh Nadarajah / Erland Sternby	
<b>Camarco - Financial PR</b>	Tel: +44 (0)20 3757 4980
Marc Cohen / Tilly Butcher / Fergus Young	OBDFinancial@camarco.co.uk

**Regulatory Disclosures (in accordance with Rule 17 and Schedule Two paragraph (g) of the AIM Rules for Companies)**

Save for the information set out below, there are no further disclosures to be made in accordance with Rule 17 and Schedule Two paragraph (g) of the AIM Rules for Companies in respect of the appointment of Mr Peter Eric Presland, aged 74. Peter has no beneficial interest in the Ordinary Shares of the Company.

**Current Directorships**

Mainvalley Limited  
Rookhill Limited  
Clausegate Limited  
Redx Pharma Ltd (formerly plc)

keox Pharma Ltd (formerly plc)  
Ashington Innovation PLC  
Purepro Solutions Limited  
Zeel Holdings Limited  
Zeel Solutions Limited

**Past Directorships**

Beautiful Information Limited  
GBR Advisory Limited  
Clear Factor Limited<sup>1</sup>

<sup>1</sup> On 18 December 2023, FRP Advisory Trading Limited (the "Administrators") were appointed as administrators to Clear Factor Limited ("Clear Factor"). Immediately following this appointment, the Administrators executed a pre-packaged sale of the business and assets to Positive for consideration, totaling £150,000. Details of the sale were circulated to creditors as part of the Proposals, which were issued in accordance with statute. The administration moved to dissolution of Clear Factor on 12 December 2024 and the company was dissolved on 12 March 2025. Clear Factor had no secured or primary preferential creditors and insufficient asset realisations to enable a distribution to unsecured creditors. The final report of the Administrators confirmed that no further investigations or actions were required in respect of any potential claims against directors.

**Notes to Editors**

**About Oxford BioDynamics Plc**

Oxford BioDynamics Plc (AIM: OBD) is an international biotechnology company, advancing personalized healthcare by developing and commercializing precision clinical diagnostic tests for life-changing diseases.

Currently OBD has two commercially available products: the [EpiSwitch® PSE](#) (EpiSwitch Prostate Screening test) and [EpiSwitch® CiRT](#) (Checkpoint Inhibitor Response Test) blood tests. PSE boosts the predictive accuracy of a PSA test from 55% to 94% when testing the presence or absence of prostate cancer. CiRT is a highly accurate (85%) predictive response test to immuno-oncology checkpoint inhibitor treatments.

The tests are based on OBD's proprietary 3D genomic biomarker platform, EpiSwitch® which enables screening, evaluation, validation and monitoring of biomarkers to diagnose patients or determine how individuals might respond to a disease or treatment.

OBD's clinical smart tests have the potential to be used across a broader range of indications, and new tests are being developed in the areas of oncology, neurology, inflammation, hepatology and animal health.

The Group's headquarters and UK laboratories are in Oxford, UK. Its US operations and clinical laboratory are in Maryland, USA, along with a reference laboratory in Penang, Malaysia.

OBD is listed on the London Stock Exchange's AIM (LSE: OBD). For more information, please visit the Company's website, [www.oxfordbiodynamics.com](http://www.oxfordbiodynamics.com), X (@OxBioDynamics) or [LinkedIn](#).

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@seg.com](mailto:rns@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

BOAUSVNRVOUOAAAR